Finch Therapeutics Group 미래 성장

Future 기준 확인 0/6

현재 Finch Therapeutics Group 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Biotechs 수익 성장	28.4%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Sep 01

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Aug 25

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

Aug 11

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Mar 15

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Dec 15

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Aug 28

Finch Therapeutics: Gut Instinct Says Buy

Jun 14

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Finch Therapeutics Group 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OTCPK:FNCH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2024	N/A	-14	-18	-18	N/A
3/31/2024	N/A	-16	-22	-22	N/A
12/31/2023	0	-75	-32	-32	N/A
9/30/2023	0	-99	-42	-42	N/A
6/30/2023	0	-137	-56	-56	N/A
3/31/2023	1	-152	-64	-63	N/A
12/31/2022	1	-115	-77	-75	N/A
9/30/2022	2	-107	-78	-74	N/A
6/30/2022	13	-76	-76	-70	N/A
3/31/2022	15	-69	-86	-78	N/A
12/31/2021	19	-58	-83	-67	N/A
9/30/2021	20	-52	-80	-64	N/A
6/30/2021	10	-52	-70	-56	N/A
3/31/2021	9	-45	-52	-41	N/A
12/31/2020	8	-39	-34	-31	N/A
12/31/2019	10	-21	-18	-17	N/A

애널리스트 미래 성장 예측

수입 대 저축률: FNCH 의 예상 수익 증가율이 절약률( 2.6% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: FNCH 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: FNCH 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: FNCH 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: FNCH 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: FNCH 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Finch Therapeutics Group 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Price target decreased to US$12.00

Price target decreased to US$27.67

Recent updates

Finch Therapeutics Files Form 15

Finch Therapeutics to Delist Its Common Stock from the Nasdaq Global Select Market on or About October 31, 2024 and Announces SEC Deregistration

Finch Therapeutics Group, Inc.(OTCPK:FNCH) dropped from NASDAQ Composite Index

Finch Therapeutics Group Receives the Delisting Letter from the Office of the General Counsel of Nasdaq Notifying the Listing Panel Determines to Delist the Company from Nasdaq

Nasdaq Listing Qualifications Department Issues an Additional Staff Determination to Finch Therapeutics Group for Continued Non-Compliance with the Market Value of Publicly Held Shares Rule

Finch Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with the Requirements of Nasdaq Listing Rule 5605(c)(2)

The Nasdaq Stock Market LLC Notifies Finch Therapeutics Regarding Company’s Status as 'Public Shell'

Finch Therapeutics Group Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

Finch Therapeutics Announces 1-for-30 Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

First quarter 2023 earnings released: US$1.33 loss per share (vs US$0.52 loss in 1Q 2022)

Finch Therapeutics Group, Inc. Reports Unaudited Consolidated Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics Group, Inc. Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

Finch Therapeutics Group, Inc. Announces Resignation of Joseph Vittiglio as Chief Business and Legal Officer and Secretary, Effective December 31, 2022

Price target decreased to US$12.00

Finch Therapeutics Group, Inc. Plans to Reduce its Workforce by Approximately 37%

Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration

Finch to get back rights to IBD product candidates after Takeda ends collaboration

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M

High number of new directors

Finch Therapeutics Group, Inc.(NasdaqGS:FNCH) dropped from Russell 2500 Value Index

Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs

Price target decreased to US$27.67

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Finch Therapeutics Group, Inc. Pauses Enrollment in PRISM4 Its Phase 3 Clinical Trial of CP101 in Recurrent C. Difficile Infection

Finch Therapeutics Group, Inc. Announces Executive Appointments

Finch Therapeutics Group, Inc. Announces U.S. Patent and Trademark Office Grants Two New Patents for FIN-211

High number of new directors

Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation

Third quarter 2021 earnings released: US$0.21 loss per share

We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully

Finch Therapeutics: Gut Instinct Says Buy

Key Executive recently bought US$12m worth of stock

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견